When was Broken String Biosciences founded?

Broken String Biosciences was founded in 2020 and raised its 1st funding round 1 year after it was founded.

Where is Broken String Biosciences located?

Broken String Biosciences is headquartered in Cambridge, United Kingdom.

Who is the current CEO of Broken String Biosciences?

Felix Dobbs of Broken String Biosciences. They have also founded 1 company.

How many employees does Broken String Biosciences have?

As of Aug 31, 2026, the latest employee count at Broken String Biosciences is 35.

Is Broken String Biosciences a funded company?

Broken String Biosciences is a funded company, having raised a total of $15M across 3 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Feb 08, 2021.

When was the latest funding round of Broken String Biosciences?

Broken String Biosciences' latest funding was a $***** Series A round on Sep 18, 2023, with participation from 5 investors.

Where does Broken String Biosciences rank among its competitors?

Broken String Biosciences ranks 10th amongst 527 active competitors, of which 77 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Twin Strand Bio, which secured $5.66M in Feb, 2025.

Who are the top competitors of Broken String Biosciences?

Broken String Biosciences' top competitors include Fabric Genomics, DNAnexus and Twin Strand Bio. Among them, Twin Strand Bio secured the most recent funding round in February, 2025.

Broken String Biosciences - 2026 Company Profile, Team, Funding, Competitors & Financials

Broken String Biosciences is a series A company based in Cambridge (United Kingdom), founded in 2020 by Felix Dobbs, Simon Reed and Patrick van Eijk. It operates as a Developer of biopharmaceutical products & cell therapies by using genome sequencing data. Broken String Biosciences has raised $15M in funding from investors like Illumina, Dieter von Holtzbrinck Ventures and Illumina Ventures. The company has 527 active competitors, including 77 funded and 37 that have exited. Its top competitors include companies like Fabric Genomics, DNAnexus and Twin Strand Bio.

Company Details

Developer of biopharmaceutical products & cell therapies by using genome sequencing data. It has developed sequencing tools that help in the development of medicines, including cell and gene therapies for the treatment of cancer, immunological health & other diseases. It develops INDUCE-seq technology for measuring DNA breaks throughout the genome & also determines the mechanism of DSB repair that facilitates the development of therapeutic genome editing.

Website: www.brokenstringbio.com/
Social

Key Metrics

Founded Year

2020

Location

Cambridge, United Kingdom

Stage

Series A

Total Funding

$15M in 3 rounds

Latest Funding Round

Series A, Sep 18, 2023, $*****

Investors

Illumina & 15 more

Ranked

10^th among 527 active competitors

Employee Count

35 as on Aug 31, 2026

Similar Companies

Fabric Genomics & 696 more

View Broken String Biosciences' full profile

Broken String Biosciences has raised a total funding of $15M over 3 rounds. Its first funding round was on Feb 08, 2021. Its latest funding round was a Series A round on Sep 18, 2023 for $*****. 5 investors participated in its latest round. Broken String Biosciences has 13 institutional investors and 3 angel investors.

Here is the list of recent funding rounds of Broken String Biosciences:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 18, 2023	6592226	Series A	9496487	6034502	1652133	7290819
Jan 21, 2022	3598295	Seed	7597234	9702469	2795425	5481072
Feb 08, 2021	2921225	Seed	5404881	7080832	Illumina	7692753

Access funding benchmarks and valuations. Sign up today!

View details of Broken String Biosciences's funding rounds and investors

The founders of Broken String Biosciences are Felix Dobbs, Simon Reed and Patrick van Eijk. Felix Dobbs is the CEO of Broken String Biosciences.

Here are the details of Broken String Biosciences' key team members:

Felix Dobbs: Co-Founder & CEO of Broken String Biosciences.
Contact Info: 1 email address
Simon Reed: Co-Founder & CSO of Broken String Biosciences.
Contact Info: 1 email address
Patrick van Eijk: Co-Founder & CTO of Broken String Biosciences.

View details of Broken String Biosciences's Founder profiles and Board Members

Broken String Biosciences' employee count trend

Broken String Biosciences has 35 employees as of Aug 26. Here is Broken String Biosciences's employee count trend over the years:

Employee count trend for Broken String Biosciences

Uncover Broken String Biosciences' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Broken String Biosciences include Fabric Genomics, DNAnexus and Twin Strand Bio. Here is the list of Top 10 competitors of Broken String Biosciences, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Fabric Genomics 2009, Oakland (United States), Acquired	AI-based disease diagnosis and genomic analysis tool for providers	$32.8M	UPMC, LDV Partners & 12 others	72/100
2nd	DNAnexus 2009, Mountain View (United States), Series H	Provider of cloud-based genome informatics & data management platform	$473M	Google Ventures, TPG & 21 others	70/100
3rd	Twin Strand Bio 2015, Seattle (United States), Series B	Developer of DNA sequencing technology to identify genomic mutations	$84M	S32, Madrona & 9 others	66/100
4th	Seven Bridges Genomics 2009, Cambridge (United States), Acquired	Biomedical data analysis company accelerating healthcare research with software and analytics	$113M	First Star Ventures, Western Technology Investment ... & 3 others	65/100
5th	Deep Genomics 2014, Toronto (Canada), Series C	AI-powered platform for RNA biology to accelerate genetic therapy discovery	$238M	SoftBank Vision Fund, True Ventures & 16 others	62/100
6th	Hexagon Bio 2017, Menlo Park (United States), Series B	Provider of bioinformatics tools for the analysis of microbial genomic sequencing data	$206M	The Column Group, Two Sigma Ventures & 10 others	62/100
7th	Envisagenics 2014, Long Island City (United States), Series B	AI-driven biotechnology company that focuses on the discovery and development of novel RNA splicing therapeutics	$46.8M	Red Cell Partners, Bristol-Myers Squibb & 17 others	61/100
8th	BC Platforms 1997, Zurich (Switzerland), Series D	Provider of a platforms for genomic data analysis and management	$47.1M	Jolt Capital, Debiopharm & 6 others	58/100
9th	Geneyx 2018, Herzliya (Israel), Seed	Provider of a clinical genetics data management platform for hospitals and genetic labs	$10M	Capri Ventures, Accenture & 5 others	57/100
10th	Broken String Biosciences 2020, Cambridge (United Kingdom), Series A	Developer of biopharmaceutical products & cell therapies by using genome sequencing data	$15M	Korys, Illumina Ventures & 14 others	52/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Broken String Biosciences's competitors? Click here to see the top ones

Broken String Biosciences has made no investments or acquisitions yet.

Here is the latest report on Broken String Biosciences's sector:

Free

Life Sciences Tech - Sector Report

Edition: September, 2026 (83 Pages)

View all reports related to Broken String Biosciences

Media has covered Broken String Biosciences for a total of 3 events in the last 1 year, 2 of them have been about company updates and 1 about people movement.